Literature DB >> 27495300

Retinal vein occlusion and the use of a dexamethasone intravitreal implant (Ozurdex) in its treatment.

Dan Călugăru1, Mihai Călugăru2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27495300     DOI： 10.1007/s00417-016-3458-z

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN： 0721-832X            Impact factor:   3.117


× No keyword cloud information.
  10 in total

1.  Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial.

Authors:  Jeffrey S Heier; Peter A Campochiaro; Linda Yau; Zhengrong Li; Namrata Saroj; Roman G Rubio; Phillip Lai
Journal:  Ophthalmology       Date:  2012-02-01       Impact factor: 12.079

2.  Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study.

Authors:  Yuichiro Ogura; Johann Roider; Jean-François Korobelnik; Frank G Holz; Christian Simader; Ursula Schmidt-Erfurth; Robert Vitti; Alyson J Berliner; Florian Hiemeyer; Brigitte Stemper; Oliver Zeitz; Rupert Sandbrink
Journal:  Am J Ophthalmol       Date:  2014-07-25       Impact factor: 5.258

3.  VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study.

Authors:  Frank G Holz; Johann Roider; Yuichiro Ogura; Jean-François Korobelnik; Christian Simader; Georg Groetzbach; Robert Vitti; Alyson J Berliner; Florian Hiemeyer; Karola Beckmann; Oliver Zeitz; Rupert Sandbrink
Journal:  Br J Ophthalmol       Date:  2013-01-07       Impact factor: 4.638

4.  Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study.

Authors:  Peter A Campochiaro; Raafay Sophie; Joel Pearlman; David M Brown; David S Boyer; Jeffrey S Heier; Dennis M Marcus; Leonard Feiner; Arun Patel
Journal:  Ophthalmology       Date:  2013-10-07       Impact factor: 12.079

5.  Intravitreal bevacizumab in acute central/hemicentral retinal vein occlusions: three-year results of a prospective clinical study.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  J Ocul Pharmacol Ther       Date:  2014-10-14       Impact factor: 2.671

6.  Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study.

Authors:  Jeffrey S Heier; W Lloyd Clark; David S Boyer; David M Brown; Robert Vitti; Alyson J Berliner; Husain Kazmi; Yu Ma; Brigitte Stemper; Oliver Zeitz; Rupert Sandbrink; Julia A Haller
Journal:  Ophthalmology       Date:  2014-03-27       Impact factor: 12.079

7.  Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study.

Authors:  Peter A Campochiaro; David M Brown; Carl C Awh; S Young Lee; Sarah Gray; Namrata Saroj; Wendy Yee Murahashi; Roman G Rubio
Journal:  Ophthalmology       Date:  2011-06-29       Impact factor: 12.079

8.  Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study.

Authors:  David M Brown; Jeffrey S Heier; W Lloyd Clark; David S Boyer; Robert Vitti; Alyson J Berliner; Oliver Zeitz; Rupert Sandbrink; Xiaoping Zhu; Julia A Haller
Journal:  Am J Ophthalmol       Date:  2012-12-04       Impact factor: 5.258

9.  Onset and duration of visual acuity improvement after dexamethasone intravitreal implant in eyes with macular edema due to retinal vein occlusion.

Authors:  Baruch D Kuppermann; Julia A Haller; Francesco Bandello; Anat Loewenstein; Jenny Jiao; Xiao-Yan Li; Scott M Whitcup
Journal:  Retina       Date:  2014-09       Impact factor: 4.256

Review 10.  Retinal vein occlusion and the use of a dexamethasone intravitreal implant (Ozurdex®) in its treatment.

Authors:  Justus G Garweg; Souska Zandi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-05-13       Impact factor: 3.117
  10 in total
  1 in total

1.  Safety and efficacy of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in Chinese patients: randomized, sham-controlled, multicenter study.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-02-04       Impact factor: 3.117
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.